Caelum Biosciences,

a Fortress Biotech Company, is a clinical stage biotechnology company developing treatments for rare and life-threatening conditions. Caelum’s lead asset, CAEL-101, is a novel antibody in Phase 1b clinical trials that is being developed for patients with AL Amyloidosis.